Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Is Sudden Pioneer In Alzheimer's Research With New Trial In Early Patients

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

With Alzheimer's disease drug research most recently characterized by setbacks, not breakthroughs, the field is shifting toward a biomarker-based approach that will allow for the treatment of patients earlier in the course of the disease – before they show symptoms.

You may also be interested in...

Amyvid Training Issues Lead To Complete Response Letter, Could Force More Trials

FDA says consistent training program needed for market implementation of amyloid diagnostic. Lilly says issues will be resolved promptly.

Lilly To Cease Development Of Alzheimer's Drug: A Blow To The Amyloid Hypothesis?

Eli Lilly said August 17 it would halt development of its Phase III Alzheimer's drug candidate semagacestat, casting some doubt on the efficacy of novel gamma secretase inhibitor drugs and slowing Lilly's late-stage pipeline as the company struggles to replace future revenues that will be lost to drugs going off patent

Bristol's Early Alzheimer's Research Takes A Different Tack

Like many other drug makers, Bristol-Myers Squibb has its eye on the potentially lucrative market for a disease-modifying Alzheimer's disease therapy. During an investor meeting March 4, management highlighted the early- to mid-stage Alzheimer's pipeline and outlined one novel approach: targeting the disease earlier before Alzheimer's symptoms develop


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts